Effect of Inhaled Albuterol in Pulmonary Hypertension

• Status: Completed
• Trial end date: 2020-07-02
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the present pilot study is to test the hypothesis that in patients with group 1 pulmonary arterial hypertension (PAH) who are on regular oral pulmonary vasodilator therapy, inhaled albuterol causes transient pulmonary vasodilation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Miami
• Treatments: Albuterol

Criteria

Inclusion Criteria:

• A Mean Pulmonary Artery Pressure >25mmHg, Pulmonary Vascular Resistance >3 wood/units and pulmonary arterial wedge pressure <15mmHg, as documented by right heart catheterization within the last 3 years

• Regular use of oral pulmonary vasodilators

Exclusion Criteria:

• Presence of chronic respiratory disease (as documented by prior lung imaging and pulmonary function tests), cardiovascular disease (as documented by prior echocardiography and/or left heart catheterization), thromboembolic PAH (as documented by pulmonary angiography)

• women of childbearing potential who do not use accepted birth- control measures

• pregnant and breast-feeding women

• respiratory infection within 4 weeks of testing

• A systemic systolic arterial BP> 150 and/or diastolic arterial BP>100 on the experiment day

• A resting O2 saturation of < 90%

• Current smoking

• BMI >35 kg/m2 and/or a diagnosis of obstructive sleep apnea

• Use of inhaled or intravenous pulmonary vasodilators